Bearing in mind that EPOR-expressing erythroid cells are the main target cells for EPO, these findings are in accordance with previously published data implying that adequate inhibition of EPO function in cancer patients might improve the therapeutic efficacy of antiangiogenic therapy (Nakamura et al., 2017). This evidence concerns the gene EPOR and cancer.